4
Changes in Ownership
Stoke Therapeutics, Inc. Filed Acc 0001522780-25-000009
Director sold 15,001 shares at an average $31.13 ($466,959)
- Director acquired 26,250 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Kaye Edward M. MD · Director
Table I: Non-derivative
6 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-12-03 | Exercise or conversion : show line 1 in the form 10b5-1 | +26,250 | 77,555 | D | ||
| 2025-12-04 | Sale : show line 2 in the form 10b5-1 | −5,222 | $30.76 | $160,647 | 72,333 | D |
| 2025-12-04 | Sale : show line 3 in the form 10b5-1 | −1,231 | $31.32 | $38,550 | 71,102 | D |
| 2025-12-05 | Sale : show line 4 in the form 10b5-1 | −6,367 | $31.33 | $199,481 | 64,735 | D |
| 2025-12-05 | Sale : show line 5 in the form 10b5-1 | −1,681 | $31.15 | $52,358 | 63,054 | D |
| 2025-12-05 | Sale : show line 6 in the form 10b5-1 | −500 | $31.85 | $15,923 | 62,554 | D |
| Open-market sales · 15,001 sh · avg $31.13 · $466,959 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2025-12-03 | Exercise or conversion : show line 7 in the form 10b5-1 Performance Stock Units | −26,250 | 0 | D |
Loading xslF345X05/form4-12062025_011216.xml…